全文获取类型
收费全文 | 118996篇 |
免费 | 5797篇 |
国内免费 | 2380篇 |
专业分类
耳鼻咽喉 | 561篇 |
儿科学 | 1543篇 |
妇产科学 | 1187篇 |
基础医学 | 14172篇 |
口腔科学 | 4008篇 |
临床医学 | 9307篇 |
内科学 | 29072篇 |
皮肤病学 | 2056篇 |
神经病学 | 8398篇 |
特种医学 | 2488篇 |
外国民族医学 | 3篇 |
外科学 | 16532篇 |
综合类 | 8110篇 |
现状与发展 | 6篇 |
一般理论 | 5篇 |
预防医学 | 8071篇 |
眼科学 | 2043篇 |
药学 | 10998篇 |
21篇 | |
中国医学 | 3907篇 |
肿瘤学 | 4685篇 |
出版年
2023年 | 983篇 |
2022年 | 1797篇 |
2021年 | 3042篇 |
2020年 | 2255篇 |
2019年 | 7667篇 |
2018年 | 7418篇 |
2017年 | 5120篇 |
2016年 | 2481篇 |
2015年 | 2599篇 |
2014年 | 4394篇 |
2013年 | 4936篇 |
2012年 | 3790篇 |
2011年 | 4296篇 |
2010年 | 3394篇 |
2009年 | 3055篇 |
2008年 | 3056篇 |
2007年 | 3223篇 |
2006年 | 2844篇 |
2005年 | 2450篇 |
2004年 | 2097篇 |
2003年 | 2008篇 |
2002年 | 1614篇 |
2001年 | 1556篇 |
2000年 | 1279篇 |
1999年 | 1195篇 |
1998年 | 921篇 |
1997年 | 969篇 |
1996年 | 741篇 |
1995年 | 751篇 |
1994年 | 641篇 |
1993年 | 504篇 |
1992年 | 472篇 |
1991年 | 373篇 |
1990年 | 272篇 |
1989年 | 263篇 |
1988年 | 222篇 |
1987年 | 210篇 |
1985年 | 3901篇 |
1984年 | 4997篇 |
1983年 | 4624篇 |
1982年 | 4538篇 |
1981年 | 4046篇 |
1980年 | 3337篇 |
1979年 | 3423篇 |
1978年 | 2808篇 |
1977年 | 2063篇 |
1976年 | 2642篇 |
1975年 | 2008篇 |
1974年 | 1752篇 |
1973年 | 1709篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
《Revista espa?ola de anestesiología y reanimación》2020,67(5):245-252
Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds.In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-CoV-2). Vitamin C, a potent antioxidant, has emerged as a relevant therapy due to its potential benefits when administered intravenous. The potential effect of vitamin C in reducing inflammation in the lungs could play a key role in lung injury caused by coronavirus infection. Another potential effective therapy is ozone: it has been extensively studied and used for many years and its effectiveness has been demonstrated so far in multiples studies. Nevertheless, our goal is not to make an exhaustive review of these therapies but spread the beneficial effects themselves.Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal. 相似文献
15.
16.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
17.
目的评估血肌酐和尿常规的常规检测基础上联合血清胱抑素C和尿微量白蛋白检测在人类免疫缺陷病毒(HIV)感染者肾功能损伤检测中的应用价值。
方法以2019年2~5月于首都医科大学附属北京地坛医院感染一科住院的169例HIV感染者为研究对象,完善其尿常规、尿微量白蛋白、血肌酐、血清胱抑素C检测;分析尿蛋白及尿微量白蛋白的阳性检出率及其差异,血肌酐升高及血清胱抑素C升高的比例及其差异。计算应用替诺福韦酯(TDF)及合并丙型肝炎、高血压、糖尿病、肿瘤的肾功能损伤的相对危险度。
结果169例HIV感染者中尿常规示尿蛋白阳性者5例(3.0%),尿微量白蛋白升高者17例(10.1%),两者阳性检出率差异具有统计学意义(χ2 = 5.9、P = 0.007)。血肌酐升高者10例(5.9%),血清胱抑素C升高者20例(11.8%),两者阳性检出率差异具有统计学意义(χ2 = 3.0、P = 0.042)。在尿常规和血肌酐检测的基础上联合检测尿微量白蛋白和血清胱抑素C的总体阳性检出率为49例(30.0%)。CD4+ T淋巴细胞计数< 200个/μl与≥ 200个/μl组患者血清胱抑素C水平分别为0.94(0.83,1.05)mg/L、0.85(0.77,0.95)mg/L,差异具有统计学意义(Z =-3.02、P = 0.003)。应用TDF及合并丙型肝炎、高血压、糖尿病、肿瘤的肾功能损伤的相对危险度分别为1.1、1.5、1.9、2.2和1.4。
结论HIV感染者中,单纯以尿常规为依据评估有无蛋白尿,以血肌酐水平为依据评估肾小球滤过功能会低估肾功能损伤的患病率。在常规检测血肌酐和尿常规的基础上联合检测血清胱抑素C和尿微量白蛋白在提高HIV感染者肾功能损伤检出率方面具有重要的应用价值。低CD4+ T淋巴细胞计数、应用TDF及合并丙型肝炎、高血压、糖尿病、肿瘤均为肾功能损伤的危险因素。 相似文献
18.
《Neuro-Chirurgie》2022,68(3):262-266
BackgroundThe prognosis for patients with recurrent glioblastoma (GBM) is dismal, and the question of repeat surgery at time of recurrence is common. Re-operation in the management of these patients remains controversial, as there is no randomized evidence of benefit. An all-inclusive pragmatic care trial is needed to evaluate the role of repeat resection.Methods3rGBM is a multicenter, pragmatic, prospective, parallel-group randomized care trial, with 1:1 allocation to repeat resection or standard care with no repeat resection. To test the hypothesis that repeat resection can improve overall survival by at least 3 months (from 6 to 9 months), 250 adult patients with prior resection of pathology-proven glioblastoma for whom the attending surgeon believes repeat resection may improve quality survival will be enrolled. A surrogate measure of quality of life, the number of days outside of hospital/nursing/palliative care facility, will also be compared. Centers are invited to participate without financial compensation and without contracts. Clinicians may apply to local authorities to approve an investigator-led in-house trial, using a common protocol, web-based randomization platform, and simple standardized case report forms.DiscussionThe 3rGBM trial is a modern transparent care research framework with no additional risks, tests, or visits other than what patients would encounter in normal care. The burden of proof remains on repeat surgical management of recurrent GBM, because this management has yet to be shown beneficial. The trial is designed to help patients and surgeons manage the uncertainty regarding optimal care.Clinical Trial Registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT04838782. 相似文献
19.
Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features
下载免费PDF全文
![点击此处可从《Histopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
20.